Subject(s)
Anger , Heart Septal Defects/surgery , Pulmonary Atresia/surgery , Stress, Psychological/complications , Takotsubo Cardiomyopathy/etiology , Ventricular Function, Left , Adult , Cardiovascular Agents/therapeutic use , Coronary Angiography , Echocardiography , Electrocardiography , Female , Heart Septal Defects/physiopathology , Humans , Pulmonary Atresia/physiopathology , Risk Factors , Takotsubo Cardiomyopathy/diagnostic imaging , Takotsubo Cardiomyopathy/drug therapy , Takotsubo Cardiomyopathy/physiopathology , Treatment OutcomeABSTRACT
AIM: To investigate the effectiveness of IgM-enriched immunoglobulins (IgM-eIVIG) in reducing short-term mortality of neonates with proven late-onset sepsis. METHODS: All VLBW infants from January 2008 to December 2012 with positive blood culture beyond 72 hours of life were enrolled in a retrospective cohort study. Newborns born after June 2010 were treated with IgM-eIVIG, 250 mg/kg/day iv for three days in addition to standard antibiotic regimen and compared to an historical cohort born before June 2010, receiving antimicrobial regimen alone. Short-term mortality (i.e. death within 7 and 21 days from treatment) was the primary outcome. Secondary outcomes were: total mortality, intraventricular hemorrhage, necrotizing enterocolitis, periventricular leukomalacia, bronchopulmonary dysplasia at discharge. RESULTS: 79 neonates (40 cases) were enrolled. No difference in birth weight, gestational age or SNAP II score (disease severity score) were found. Significantly reduced short-term mortality was found in treated infants (22% vs 46%; p = 0.005) considering all microbial aetiologies and the subgroup affected by Candida spp. Secondary outcomes were not different between groups. CONCLUSION: This hypothesis-generator study shows that IgM-eIVIG is an effective adjuvant therapy in VLBW infants with proven sepsis. Randomized controlled trials are warranted to confirm this pilot observation.
